(Q42207559)

English

PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era.

scientific article published on 23 October 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PSA response to neoadjuvant androgen deprivation therapy is a strong independent predictor of survival in high-risk prostate cancer in the dose-escalated radiation therapy era. (English)

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

adaptive radiation therapy

0 references

4

object named as

Mark F Munsell

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

14

object named as

Deborah A Kuban

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Lawrence B Levy

5

object named as

Lawrence B Levy

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Karen E Hoffman

9

object named as

Karen E Hoffman

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Seungtaek L Choi

7

object named as

Seungtaek L Choi

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Christopher Logothetis

13

object named as

Christopher J Logothetis

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Rajat J Kudchadker

6

object named as

Rajat J Kudchadker

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Thomas A.M. Pugh

10

object named as

Thomas J Pugh

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Sean E. McGuire

1

object named as

Sean E McGuire

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

11

object named as

Steven J Frank

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

author name string

Andrew K Lee

2

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Jasmina Z Cerne

3

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Quynh N Nguyen

8

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Paul G Corn

12

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

language of work or name

0 references

publication date

23 October 2012

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

International Journal of Radiation Oncology Biology Physics

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

85

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

1

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

e39-46

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

26 October 2017

Failure to achieve a PSA level <or=1 ng/mL after neoadjuvant LHRHa therapy predicts for lower biochemical control rate and overall survival in localized prostate cancer treated with radiotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

26 October 2017

Phase II study of neoadjuvant androgen deprivation followed by external-beam radiotherapy with 9 months of androgen deprivation for intermediate- to high-risk localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

26 October 2017

Neoadjuvant hormone therapy and external-beam radiation for localized high-risk prostate cancer: the importance of PSA nadir before radiation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

26 October 2017

6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

26 October 2017

Non-parametric confidence interval estimation for competing risks analysis: application to contraceptive data

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

26 October 2017

Is biochemical response more important than duration of neoadjuvant hormone therapy before radiotherapy for clinically localized prostate cancer? An analysis of the 3- versus 8-month randomized trial.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

17 August 2018

Final report of multicenter Canadian Phase III randomized trial of 3 versus 8 months of neoadjuvant androgen deprivation therapy before conventional-dose radiotherapy for clinically localized prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

17 August 2018

Escalated-dose versus standard-dose conformal radiotherapy in prostate cancer: first results from the MRC RT01 randomised controlled trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

17 August 2018

Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma--long-term results of phase III RTOG 85-31.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

17 August 2018

Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: the Radiation Therapy Oncology Group Protocol 92-02.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

17 August 2018

Long-term results with immediate androgen suppression and external irradiation in patients with locally advanced prostate cancer (an EORTC study): a phase III randomised trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

17 August 2018

Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

17 August 2018

Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

17 August 2018

Prostate specific antigen in black and white men after hormonal therapies for prostate cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3840533

17 August 2018

Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/23102837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Predictors of improved outcome for patients with localized prostate cancer treated with neoadjuvant androgen ablation therapy and three-dimensional conformal radiotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/23102837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Androgen deprivation and radiation therapy: sequencing studies using the Shionogi in vivo tumor system

1 reference

https://pubmed.ncbi.nlm.nih.gov/23102837

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.IJROBP.2012.08.036

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 October 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42207559&oldid=2058330828"